Pliant Therapeutics presents well-tolerated bexotegrast data at ATS 2024 for IPF and PSC, with FDA Fast Track and Orphan Drug Designations.
Pliant Therapeutics presented data at the ATS 2024 Conference for bexotegrast, a dual-selective integrin inhibitor for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). Bexotegrast demonstrated well-tolerance in Phase 1 and 2 trials with minimal adverse effects. The drug has received Fast Track Designation and Orphan Drug Designation for both IPF and PSC from the FDA.
May 21, 2024
3 Articles